Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-20-028070
Date:2020-05-06
Issuer: ADVERUM BIOTECHNOLOGIES, INC. (ADVM)
Original Submission Date:

Reporting Person:

PATTERSON LEONE D
C/O ADVERUM BIOTECHNOLOGIES, INC.
800 SAGINAW DRIVE REDWOOD CITY, CA 94063

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-05-06 M 20,000 a $3.44 143,659 direct
COMMON STOCK 2020-05-06 S 20,000 d $20.02 123,659 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 3.44 2020-05-06 deemed execution date M 20,000 (d) 2026-06-15 common stock 20,000 $3.44 155,576 direct
Footnotes
IDfootnote
f1 the balance of shares reflected in reporting person's prior form 4 was inadvertently reflected as 123,429 shares and should have been reflected as 123,659 shares. the form 4 originally reflecting the incorrect balance, filed with the sec on 2/10/2020, has been amended to reflect the correct end of period balance in column 5 of table i in that filing.
f2 this transaction was pursuant to a 10b5-1 plan.
f3 represents weighted average sales price. the shares were sold at prices ranging from $20.00 to $20.09. the reporting person will provide upon request, to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f4 twenty-five percent (25%) of the total shares subject to the option vest and become exercisable on the first anniversary of the vesting commencement date, and 1/48 of the total shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall be vested and exercisable as of the fourth anniversary of the vesting commencement date, subject to the reporting person's continued service with the issuer on each such vesting date.
WhaleWisdom Logo

Elevate your investments